Hplus d'une centaine d'approches alternatives en cancérologie, qui ont été démontrées comme étant scientifiquement en cliniquement supérieures à l'allopathie hégémonique de l'Etat, ci-après l'approche des toxines ou vaccins du Dr Coley, ce qui fait suite à la demande d'André.

HYPERTHERMIE, VACIN DE COLEY, IMMUNOLOGIE ET CANCER

Dr. A. Lwoff, famous French bacteriologist, (Nobel prize winner) has demonstrated in repeated scientific ex

Le Dr. Coley, chirurgien américain qui deviendra chef de service des tumeurs osseuses au memorial hospital de New York a une brillante carrière malgré l'échec du traitement des cancers. C'est dans les années 1890, alors que la chirurgie est encore le seul traitement des tumeurs malignes, qu'il observe la régression d'un cancer du cou (qui avait récidivé après plusieurs interventions) à la suite d'une infection par streptocoque donnant un érysipèle. Alors que les cancers sont rattachés à une possible origine infectieuse et que l'immunothérapie des cancers commence à être essayée, le Dr Coley retrouve dans la littérature des cas comparables et inocule des streptocoques à des malades cancéreux pour provoquer l'infection. Il observe quelques rémissions mais aussi des accidents, ce qui le conduit à remplacer l'inoculation de bactéries vivantes et virulentes par des germes inactivés présentés sous forme de toxines qui prennent son nom. Différentes préparations sont proposées et utilisées avec succès. Toutefois, après quelques résultats dits fragmentaires, les toxines de coley seront abandonnées à partir de 1910 par le "establishment", avec le développement de la radiothérapie et une opposition déterminée du directeur de recherche du memorial hospital James Ewing, malgré les efforts de leur promoteur (même "black out" pour Tesla). Après la création en 1953 du New York cancer research institute (grâce à un don de Nelson Rockfeller) consacré à l'immunologie des tumeurs malignes, sa fille Helen Nauts ne réussira pas à les relancer durablement ni à empêcher qu'elles soient classées en 1965 comme " remèdes non prouvés"'. Dans les années 1980, des médecins chinois s'y intéresseront de nouveau comme une ' immunothérapie économique pour le tiers-monde '. Des études récentes ont suggéré que les effets observés avec les toxines de coley pouvaient être dus au facteur nécrosant des tumeurs (tnf).

Comme on l'a vu au Congrès de Marcevol, le provocation de la fièvre de façon artificielle fonctionne pour la simple raison qu'une cellule cancéreuse est plus faible devant la chaleur qu'une cellule saine, comme pour l'oxygène, l'urine, la restriction protéique ciblée, enzymes, certaines molécules et plantes etc. Le mécanisme de la fièvre est semblable à l'hyperthermie, que l'on utilise beaucoup en naturopathie. Élévation locale ou générale de la température du corps, au-dessus du chiffre normal de 37-37,5° celsius (on parle de fièvre quand elle traduit une maladie), l'hyperthermie a été depuis longtemps proposée pour traiter les cancers. Le papyrus médical égyptien "Edwin-Smith", vieux de près de quatre mille ans, rapporte une tentative de traitement d'un cancer du sein à l'aide d'une ' tige chauffée '. Hippocrate en fait état dans ses aphorismes et, à sa suite, plusieurs médecins proposeront de ' cautériser ' certaines tumeurs superficielles, mais il faut attendre le xix siècle pour que l'hyperthermie trouve réellement une place dans le traitement des cancers, après Bichat pour qui "... il est vrai que la fièvre soit un instrument de guérison", et partisan de la " pyrétothérapie". A ce moment, des médecins observent des cas de régression, voire quelques guérisons d'authentiques de cancers à la suite de grands états fébriles occasionnés par des infections. On cherche alors à créer des fièvres artificielles, principalement à l'aide de toxines, dont la plus utilisée fut celle du Dr Coley. Mais l'hégémonie de la radiothérapie étouffe le developpement de cette approche, jusque dans les années 1960-1970, à la lumière de solides études scientifiques, l'hyperthermie anticancéreuse renaît de ses cendres. Les chercheurs démontrent qu'une élévation thermique de 6 à 8°c au dessus de 37°c, maintenue plusieurs heures, est toxique pour les cellules de mammifères et donc pour les cellules tumorales. Les cellules à ph bas, celles en phase de synthèse du cycle cellulaire ou celles vivant en milieu appauvri paraissent plus sensibles à cette action toxique. Or ce sont les cellules les plus difficiles à détruire par les rayonnements ionisants. Les modes d'action respectifs de l'hyperthermie et de la radiothérapie se révèlent donc complémentaires, tandis que des études en laboratoire montrent que l'hyperthermie augmente l'efficacité de la radiothérapie. Ce même effet potentialisateur s'observe quand l'hyperthermie accompagne certains médicaments de chimiothérapie."Les bases théoriques de l'hyperthermie en cancérologie sont donc prometteuses et les premiers essais cliniques commencent dans les années 1970. Grâce à divers appareils, utilisant les micro-ondes, les radio-fréquences ou les ultra-sons, on parvient à chauffer de façon satisfaisante des tumeurs superficielles et à améliorer les résultats de la radiothérapie associée ou meme d'autres thérapies de terrain, par exemple pour les récidives locales de cancer du sein. L'hyperthermie interstitielle, qui chauffe les tumeurs à l'aide de sondes implantées et s'associe à la curiethérapie, est aussi efficace; mais cette technique est limitée par l'impossibilité d'implanter sondes ou antennes dans bien des tumeurs malignes. Les tumeurs profondes, dans le thorax ou l'abdomen, échappent aux possibilités de l'hyperthermie classique. Toutefois, avec la technique du sport intense, des bains de vapeurs, des bains chaud et des toxine infectueuse, l'on peut avoir raison de tout cancer, surtout s'il ces techniques sont accompagnées d'autres thérapies de terrain que nous avons vu au Congrès de Marcevol.

La mort des cellules cancéreuses est donc un évènement essentiel pour l'induction d'une réponse immunitaire spécifique. La grande chaleur provoqué par du sport intense, par des infections, par l'hyperthermie est une arme redoutable que la cancérologie orthodoxe néglige. La chaleur fait murir la réponse immunitaire, encourage la maturation des cellules dendritiques, activation des macrophages, (signal danger) et contribue a faire "fondre" une tumeur et ses métastases.

Dendritic cells are the key "education centers" in activating immune response memory to increase the system's ability to fight off familiar antigens.

Parmis des milliers de personnes guéries par cette méthode, voici un témoignage, une personne atteinte d'un lymphome guérie à la clinique*********8888**************** de Chipsa au Mexique.

Coley's Toxins a.k.a. Mixed Bacterial Vaccine (MBV)
History
In 1888, Dr. William B. Coley (1862-1936), Harvard Medical School graduate, and eminent New York City surgeon and Sloan-Kettering researcher, stumbled across one of the most intriguing findings ever made in cancer research. In fact, his invention was a starting point for all modern immunotherapy. His discovery was first tolerated, then ridiculed, and finally suppressed, although in recent years some new interest in his discovery has emerged among researchers.
Frustrated after losing his first patient at Memorial Hospital, a 19 year old female bone cancer patient, despite an early detection followed by prompt amputation of her arm and a good prognosis, Coley began methodically searching the patient records at New York Hospital . He went back 15 years and examined records of all bone cancer patients. Most cases ended in failure and death. To his amazament, however, Coley discovered one patient who had been given up for lost by his doctors and yet had walked out of the hospital in apparently perfect health [1]. On his deathbed, this patient had suffered two attacks of erysipelas, a severe skin infection caused by bacteria Streptococcus pyogenes.

Coley's first attempts to produce reaction in cancer patients by injecting streptococcus cultures into them ended in failure. Luckily, he managed to get a particularly virulent culture from a famous German bacteriologist, Robert Koch, through a friend. The patient who received this culture developed a severe case of erysipelas with high fever. Within a few days the tumors on his tonsils and neck completely disappeared. In 1893 Coley published his first paper on the new method [2].

Because using live bacteria was dangerous and caused an ordeal for the patient, Coley later tried to and succeeded in improving his method. Instead of using bacteria, he mixed the toxins of the strep with those of another germ, Bacillus prodigiosus, which today is called Serratia marcesens. This seemed to work similarly to the live culture.

Best results were obtained when Dr. Coley or his colleague supervised the production of toxins. Parke-Davis, the pharmaceutical company, also produced the toxins commercially for many years, but they heated the formula, which reduced its effectiviness. Despite that, even this weakened form of toxins, Parke-Davis formula #IX, showed 37 percent cure rate for inoperable patients.

In 1943 NCI researcher M.J. Shears discovered that the biologically active substance in Coley's toxins is lipopolysaccharide (LPS), which occurs in the cell walls of gram-negative bacteria [4].

By 1953, however, all the production of the toxins in the United States stopped.

For over 30 years starting late 50s or early 60s, Dr. France Havas, professor emeritus of the Department of Microbiology and Immunology at Temple University School of Medicine, Philadelphia, studied the effects of Coley's toxins in mice and humans. The results of her studies were generally favorable, even in advanced patients [5,6,7,8].

In 1976 randomized trials of mixed bacterial vaccines (MBV) - as Coley's toxins are now called - begun at Memorial Sloan-Kettering.

In 1991 K.F.Kolmel and colleagues in Gottingen, Germany reported on favorable results obtained on treatment of advanced melanoma with Coley's toxins [9].

Recently Coley's toxins have been researched and used also in China. Zhao and others published 1991 preliminary results of these trials [10].

ProofColey's results have been tabulated by his daughter, Helen Coley Nauts, D.Sc., former executive director of the Cancer Research Institute, Inc., in New York City [11]. She and her medical colleagues have documented 894 cases treated with Coley's vaccine. Examples:

Tumor type # of operable Alive after # of inoper. Alive after
patients 5 years patients 5 years

Giant cell
bone tumor 38 33 (87%) 19 15 (79%)

Breast cancer 13 13 (100%) 20 13 (65%)

Other 5-year survival rates: 67% in Hodgkin's disease, 67% in inoperable ovarian cancer, 60% in inoperable malignant melanoma. Overall, patients with inoperable tumor of various kinds had 45% 5-year survival, while those with operable tumors had 50%.

In 1962, Dr. Barbara Johnston, M.D. published a double blind study on Coley's toxins. This study was conducted at New York University-Bellevue Hospital. The results were clear-cut. In the control group treated with fever inducing placebo, only one patient of 37 showed any signs of improvement. Of the 34 patients treated with Coley's toxins, 18 showed no improvement, 7 noted decreased pain while 9 showed such benefits as tumor necrosis, apparent inhibition of metastases, shrinkage of lymph nodes, and disappearance of tumors [12].

In 1982 at the conference held in Cologne, Germany, Mrs. Nauts reported the first results of randomized trials of MBV (Coley's toxins) begun in 1976 at Memorial Sloan-Kettering: Advanced non-Hodgkin's lymphoma patients receiving MBV had a 93 percent remission rate as opposed to 29 percent for controls who received chemotherapy alone [13].

References

[1] Cancer Research Institute. Review of Progress and Hope. New York 1976.

[2] Coley, William B. "A Preliminary Note on the Treatment of Inoperable Sarcoma by the Toxic Product of Erysipelas." Post-graduate 8:278-86, 1893.

[3] Coley, William B. "The Cancer Symposium at Lake Mohonk." American Journal of Surgery (New Series) 1:222-25, October 1926.

[4] Ward, Patricia Spain. Memo to John Gibbons. December 2 1988.

[5] Havas H, et al. Mixed bacterial toxins in the treatment of tumors. I. Methods of preparation and effects on normal or Sarcoma 37-bearing mice. Cancer Res. 1958;18:141-148.

[6] Havas H, et al. Mixed bacterial toxins in the treatment of tumors. III. Effect of tumor removal on the toxicity and mortality rates in mice. Cancer Res. 1960;20:393-396

[7] Havas H, and Donnelly A. Mixed bacterial toxins in the treatment of tumors. IV. Response of methylcholanthrene-induced, spontaneous, and transplanted tumors in mice. Cancer Res. 1961;21:17-25.

[8] Havas H, et al. The effect of bacterial vaccine on tumors and immune response of ICR/Ha mice. J Biol Res Mod. 1990;9;:194-204.

[9] Kolmel K, et al. Treatment of advanced malignant melanoma by a pyrogenic bacterial lysate. A pilot study. Onkologie. 1991;14:411-417.

[10] Zhao YT, et al. Preliminary reult of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol & Tumor Pharmacother. 1991;8:23-28.

[11] Nauts, Helen Coley. Immunotherapy of Cancer by Bacterial Vaccines. Paper read at International Symposium on Detection and Prevention of Cancer. New York, April 25 - May 1, 1976.

[12] Johnston, Barbara, "Clinical Effects of Coley's Toxin. 1. Controlled Study. 2. A Seven-Year Study." Cancer Chemotherapy Reports 21:19-68, August 1962.

[13] Nauts, Helen Coley, Bacterial Products in the Treatment of Cancer: Past, Present and Future. Paper read at the International Colloqium on Bacteriology and Cancer, Clogne, Federal Republic of Germany, March 16-18, 1982.

[14] Nauts, Helen Coley, Bacterial vaccine therapy of cancer. Dev Biol Stand. 1977;38487-94.

[15] Nauts, Helen Coley, Bacterial pyrogens: bemeficial effect on cancer patients. Prog Clin Biol Res. 1982;107:687-96.

[16] Nauts, Helen Cole, Bacteraia and cancer - antagonisms and benefits, Cancer Surv. 1989;8:713-23.

[17] Keen AR and Frelick RW, Response of tumors to thermodynamic stimulation of the immune system. Del Med J. 1990;62:1115-6.

[18] Cunningham RS and Pearson FC. ImuVert activation of natural killer cytotoxicity and interferon gamma production via CD16 triggering. Int J Immunopharmacol. 1990;12:589-98.

[19] Jimenez JJ et al. Treatment with ImuVert aborts development of chloroleukemia in newborn rats. J Biol Response Mod. 1990;9:300-4.

[20] Cress NB, et al. ImuVert therapy in the treatment of recurrent malignant astrocytomas: nursing implications. J Neorosci. Nurs. 1991;23:29-33.

[21] Jaeckle KA, et al. Phase II trial of Serratia marcesenses extract in recurrent malignant astrocytoma. J Clin Oncol. 1990;8:1408-18.

[22] Abe H. [antitumor effect of LPS immobilized beads]. Nippon Geka Gakkai Zasshi. 1991;92:627-35.

Dr. A. Lwoff, famous French bacteriologist, (Nobel prize winner) has demonstrated in repeated scientific experiments that fever is indeed a "great medicine," and that it can help to cure many "incurable diseases". In health and spa clinics in Europe, artificially induced fever, mostly in the form of overheating baths, has been used successfully to treat such conditions as rheumatic diseases, skin disorders, insomnia, arthritis - and cancer. Dr. Josef Issels has said, "Artificially induced fever has the greatest potential in the treatment of many diseases, including cancer." Give me a chance to create a fever and I will cure any disease," said the great ancient physician Parmenides. Many modern giants of biological medicine in Europe in addition to Lwoff have adopted hyperthermia for cancer. The famous German cancer specialist, Prof. Werner Zabel, (the director of one of the most successful cancer clinics in the world, the Ringberg-Klinik), Dr. Josef Issels, and other have used the technique to artificially induced fever in their battle against cancer. When medical science saw its birth, healing disease with water was recognized as one of the most important therapeutic modalities. Hippocrates, Celus, Galen and other ancient greats of medicine praised water for its many curative properties. In all major ancient civilizations, bathing was held in esteem not only for its remedial properties, but as an important health-building and disease-preventive measure. In more modern times, the therapeutic properties of water were popularized by Father Kneipp, a French priest of the 16th century, as well as by , Maria Schlenz, Priessnitz, and other European water-cure pioneers. There are hundreds of Spas and "Bads" in most European countries where therapeutic baths are used as a major healing measure, especially so-called Kneipp-baths. As Father Kneipp said, "Water contains great healing power" - and millions of yearly visitors to these "bads" can testify that water, indeed, does possess great therapeutic value, Lourdes included.

DAVANTAGE D'INFO SUR L'HYPERTHERMIA, ULTÉRIEUREMENT